Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation.
1. A method of treating a blood coagulation disorder comprising the step of administering a pharmaceutical preparation comprising an effective amount of a molecule selected from the group consisting of vWF-propeptide (pp-vWF) and pro-vWF to a patient.
2. The method according to claim 1 , wherein the blood coagulation disorder is selected from the group consisting of von Willebrand's disease, phenotypic hemophilia, hemophilia A and factor VIII inhibitors.
3. The method according to claim 1 , wherein the pharmaceutical preparation further comprises an effective amount of a hemostasis protein selected from the group consisting of mature vWF, factor VIII, activated blood coagulation factors, blood factors with factor eight inhibitor bypassing (FEIB) activity and FEIBA.
4. A method according to claim 3 , wherein pro-vWF is complexed to factor VIII.
5. The method according to claim 3 , wherein the thrombosis risk of the patient is reduced when compared to patients treated with a pharmaceutical preparation not comprising an effective amount of a molecule selected from the group consisting of pp-vWF and pro-vWF.
6. The method according to claim 1 , wherein the pharmaceutical preparation further comprises an effective amount of a platelet component selected from the group consisting of collagen, platelet glycoprotein, a platelet, fibrinogen, fibrin, or heparin.
7. A method of treating a patient at risk of a blood coagulation disorder comprising the step of administering a pharmaceutical preparation comprising an effective amount of a molecule selected from the group consisting of vWF propeptide (pp-vWF) and pro-vWF to a patient, wherein the blood coagulation disorder is selected from the group consisting of von Willebrand's disease, phenotypic hemophilia, hemophilia A and factor VIII inhibitors.